OncRef

Clinical Trial: NCT03528642

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-09-22

Study Overview

Brief Summary

This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. Telaglenastat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving telaglenastat with radiation therapy and temozolomide may work better than surgery, radiation therapy, and temozolomide in treating patients with IDH-mutated diffuse astrocytoma or anaplastic astrocytoma.

Official Title

A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

Conditions

Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3

Intervention / Treatment

  • Other: Questionnaire Administration
  • Radiation: Radiation Therapy
  • Drug: Telaglenastat Hydrochloride
  • Drug: Temozolomide

Other Study ID Numbers

  • NCI-2018-00876
  • NCI-2018-00876
  • 10218
  • 10218
  • UM1CA186686
  • UM1CA186709

Start Date (Actual)

2019-05-01

Primary Completion Date (Actual)

2024-12-10

Study Completion Date (Estimated)

2027-09-18

Enrollment (Actual)

23

Study Type

Interventional

Phase

Phase 1